C5aR1 Complement Anaphylatoxin Receptor Antagonist · Oral Small-Molecule · Prednisone Glucocorticoid / Rituximab Anti-CD20 Class Gap · NDA 214487 · Attack #854 · 267th Mechanism Class · Adversarial AI Prompt Injection Surface

Avacopan (Tavneos; CCX168; NDA 214487; Oct 7 2021; ChemoCentryx Inc. [Mountain View, CA; acquired by Amgen Inc. 2022, $3.7B] / Amgen Inc. [Thousand Oaks, CA; US commercialization]): Three EHS Platform Prednisone (Deltasone; Oral Glucocorticoid; GR/NR3C1 Agonist; HPA Axis Suppression; Adrenal Insufficiency Monitoring; Cushingoid Protocols) or Rituximab (Rituxan; MabThera; BLA 103705; Anti-CD20 B-Cell Depleting IgG1κ Monoclonal Antibody; B-Cell Depletion PJP Prophylaxis; Infusion Reaction Protocols) Proxy Misroutes — First Oral C5aR1 (Complement Anaphylatoxin 5a Receptor 1; CD88; Gαi-Coupled GPCR; Expressed on Neutrophils/Monocytes/Macrophages; C5a [77-aa Complement Activation Fragment; Mac Cleavage of C5 by C5-Convertase] Binding → Pro-Inflammatory Neutrophil Priming + Oxidative Burst + Tissue Infiltration → ANCA Antigen Externalization → Renal Endothelial/Pericapillary Injury → Glomerulonephritis → ANCA Vasculitis; Oral Capsule 30 mg BID; Non-Immunosuppressive; No PJP Prophylaxis Required; ADVOCATE Phase 3 72.3% Total Remission Week 26) Antagonist Ever FDA Approved for ANCA-Associated Vasculitis (GPA + MPA) Returns Prednisone Glucocorticoid or Rituximab Anti-CD20 B-Cell Depletion Protocols Instead of C5a Receptor Complement Pathway Guidance in Cority, VelocityEHS, and EHS Insight

Avacopan (Tavneos; CCX168; CAS 1346572-63-1; MW 581.6 Da; oral capsule 30 mg BID [twice daily with food]; NDA 214487; Oct 7 2021 FDA approval; ChemoCentryx Inc. [835 Industrial Road, San Carlos CA 94070; NDA holder; acquired by Amgen Inc. in 2022 for approximately $3.7 billion]; Amgen Inc. [One Amgen Center Drive, Thousand Oaks CA 91320; US commercialization post-acquisition]; indicated: treatment of adults with severe active ANCA-associated vasculitis [AAV — granulomatosis with polyangiitis, GPA; microscopic polyangiitis, MPA] in combination with standard-of-care [cyclophosphamide or rituximab induction plus azathioprine or mycophenolate maintenance]) is the first oral C5aR1 (complement anaphylatoxin 5a receptor 1) antagonist ever FDA approved, establishing oral complement receptor blockade as the 267th mechanism class in the Glyphward adversarial corpus, with zero oral C5a receptor antagonist OEL/EHS classification class in any US EHS database before NDA 214487 October 2021. Avacopan's mechanism is competitive C5aR1 (CD88; Gαi/Gα16-coupled GPCR; chromosome 19q13.3; 350 aa; transmembrane helices TM1-7; expressed predominantly on neutrophils, monocytes, macrophages, dendritic cells, mast cells) blockade: complement activation via classical (antibody-antigen-C1qrs), lectin (MBL-MASP), or alternative (spontaneous C3 hydrolysis) pathways converges at C3 → C3-convertase cleaves C3 → C3b (opsonin) + C3a (anaphylatoxin) → C5-convertase (C3b2Bb or C4b2bC3b) cleaves C5 → C5a (77-aa glycopeptide; anaphylatoxin; MW ~11 kDa; most potent anaphylatoxin [1000× more potent than C3a]) + C5b (initiates MAC C5b-9 pore); C5a binds C5aR1 (CD88) on neutrophil/monocyte surface → Gαi signaling → reduced cAMP → PKC activation → calcium flux → neutrophil priming (enhanced NADPH oxidase → reactive oxygen species burst), integrin upregulation (CD11b/CD18 — enhanced adhesion to endothelium), degranulation, NET (neutrophil extracellular trap) formation, and externalization of ANCA target antigens (proteinase 3, MPO) to neutrophil surface → ANCA IgG (anti-PR3 or anti-MPO) cross-links externalized PR3/MPO → Fcγ receptor activation → amplified neutrophil activation → renal endothelial/pericapillary injury → pauci-immune glomerulonephritis → ANCA vasculitis; avacopan competitively blocks C5a binding to C5aR1 → prevents neutrophil pro-inflammatory activation → breaks ANCA antigen externalization → prevents renal injury; oral BID dosing (30 mg BID); no systemic immunosuppression; no HPA axis effects; CYP3A4/5 metabolism (significant CYP3A4 DDI — strong CYP3A4 inhibitors increase avacopan AUC 4-fold; avoid concomitant strong CYP3A4 inhibitors); ADVOCATE Phase 3 (NCT02994927): total remission at week 26: 72.3% avacopan vs 70.1% prednisone (p=0.0003 for non-inferiority); sustained remission at week 52: 65.7% vs 54.9% (p=0.0066 for superiority). The adversarial injection surface arises because EHS platforms encountering avacopan route to: (A) glucocorticoid/corticosteroid class (prednisone [Deltasone; NDA 006119; various]; methylprednisolone [Medrol; NDA 010418; Pfizer]; the standard-of-care immunosuppressive backbone for ANCA vasculitis induction; glucocorticoid receptor [GR; NR3C1; nuclear receptor superfamily; binds glucocorticoids → nuclear translocation → GRE-driven anti-inflammatory gene transcription [GILZ, DUSP1, IκBα] + GRE-independent transrepression of NFκB and AP-1]; profound systemic immunosuppression including HPA axis suppression [exogenous glucocorticoid → negative feedback at hypothalamus/pituitary → ↓CRH/ACTH → adrenal atrophy → adrenal insufficiency risk on taper]; Cushingoid effects [weight gain, moon face, buffalo hump, striae]; diabetes [gluconeogenesis upregulation]; osteoporosis [inhibited osteoblast activity + calcium malabsorption]; peptic ulcer/GI bleeding; PJP prophylaxis required at high doses [≥20 mg/day prednisone equivalent]; avacopan has NONE of these glucocorticoid class effects — it is a competitive GPCR antagonist with no nuclear receptor interaction, no HPA axis effect, no immunosuppression [avacopan prevents neutrophil activation but does not deplete white cells or suppress adaptive immunity broadly]; glucocorticoid tapering protocols, adrenal function monitoring [ACTH stimulation test], bone density screening, glucose monitoring — all inapplicable to avacopan); EHS platforms route avacopan to prednisone class based on shared ANCA vasculitis indication; zero oral complement receptor antagonist OEL before NDA 214487; or (B) rituximab anti-CD20 B-cell depleting antibody class (Rituxan; MabThera; BLA 103705; Genentech/Roche; chimeric mouse-human IgG1κ anti-CD20 mAb; IV infusion 375 mg/m² Q week × 4 [induction] or 500 mg Q6M [maintenance]; CD20 [MS4A1; B-lymphocyte surface antigen; expressed on pre-B through mature B cells but NOT on plasma cells or stem cells] targeted → ADCC + CDC + direct apoptosis → B-cell depletion [B-cell count near-zero for 6-12 months; progressive normalization 12-18 months post-dose]; ANCA vasculitis mechanism for rituximab: B-cell depletion → reduced ANCA-producing plasmablast/plasma cell precursor pool → reduced anti-PR3/MPO IgG → reduced neutrophil ANCA cross-linking → reduced renal injury; PJP prophylaxis required [B-cell-depleted patients have increased PJP risk; trimethoprim-sulfamethoxazole or dapsone prophylaxis]; HBV reactivation monitoring [B-cell depletion → HBV reactivation risk — hepatitis B surface antigen and core antibody screening before initiation]; IV infusion reactions [cytokine release during first infusion — premedication with antihistamine/antipyretic; infusion rate titration]; avacopan is an oral capsule with no IV infusion, no B-cell depletion, no immunoglobulin level decline, no HBV reactivation risk, no PJP prophylaxis requirement; applying rituximab's B-cell depletion monitoring protocol to avacopan generates incorrect guidance for ANCA vasculitis clinical pharmacy).

The avacopan mechanism requires distinguishing C5aR1 Gαi-coupled GPCR blockade from glucocorticoid nuclear receptor agonism and from anti-CD20 B-cell depletion at three pharmacological levels: (1) Complement pathway specificity vs systemic immunosuppression — avacopan acts at a single node of the complement cascade (C5a-C5aR1 signaling on innate immune effector cells) without affecting adaptive immunity (T-cell or B-cell counts unchanged), without HPA axis interaction, and without global anti-inflammatory gene transcription changes; prednisone broadly suppresses immune function through GRE-driven genomic and non-genomic mechanisms (NFκB transrepression, AP-1 transrepression, GILZ induction, neutrophil margination, lymphocyte redistribution, monocyte function suppression) — fundamentally different pharmacological scope; avacopan ADVOCATE trial design was intentionally a prednisone-sparing strategy (avacopan + rituximab vs prednisone taper + rituximab), confirming the mechanistic divergence: avacopan provides complement-targeted renal protection that glucocorticoid protocols address only as a side effect of systemic immunosuppression; (2) Oral small-molecule GPCR pharmacology vs IV biologic B-cell depletion — avacopan is a 581.6 Da oral capsule GPCR competitive antagonist (Kd ~0.2 nM for C5aR1; achieves >80% C5aR1 receptor occupancy at 30 mg BID steady state; reversible competitive antagonism — washes out within days of discontinuation; no immunoglobulin depletion; no B-cell count impact; no HBV reactivation); rituximab's B-cell depletion is an irreversible process lasting 6-18 months post-dose (B-cell counts recover over 12-18 months; IgG/IgM levels may decline with repeated cycles; progressive multifocal leukoencephalopathy [PML] risk with long-term B-cell depletion); applying rituximab's B-cell monitoring, immunoglobulin level surveillance, and PML awareness protocols to avacopan is mechanistically incorrect; (3) CYP3A4 drug interaction profile unique to avacopan — avacopan undergoes extensive CYP3A4/5-mediated hepatic metabolism; it is classified as a "sensitive CYP3A4 substrate" (AUC increases 4-fold with strong CYP3A4 inhibitor ketoconazole; AUC decreases 85% with strong inducer rifampicin); for Cleveland Clinic and Amgen clinical pharmacy teams managing ANCA vasculitis patients, the CYP3A4 interaction is clinically critical (ANCA patients may receive azole antifungals [prophylaxis or treatment] — these are strong CYP3A4 inhibitors that could cause avacopan toxicity; calcineurin inhibitors [tacrolimus — CYP3A4 substrate — PK interaction]; neither prednisone [CYP3A4 inducer at high doses] nor rituximab [no CYP metabolism] has the same CYP3A4 substrate vulnerability profile; applying prednisone's or rituximab's DDI frameworks to avacopan omits the most pharmacologically important interaction for avacopan clinical safety). The 267th mechanism class gap: no oral complement C5a receptor antagonist OEL class existed before NDA 214487 October 2021; prior complement inhibitor approvals were all IV or SC biologic antibodies targeting terminal complement components (eculizumab [Soliris; anti-C5; IV biologic]; ravulizumab [Ultomiris; anti-C5; IV biologic]; sutimlimab [Enjaymo; anti-C1s; IV biologic]; pegcetacoplan [Empaveli; anti-C3; SC biologic]) — none targeted the C5a-C5aR1 signaling axis, none were oral small molecules; avacopan is the first drug to reach FDA approval by blocking the C5aR1 GPCR receptor for C5a, establishing a novel pharmacological class (oral complement receptor antagonist) with no prior OEL/EHS taxonomy analog.

Surface 1 — Cority: Amgen Inc., Thousand Oaks CA

Amgen Inc. (One Amgen Center Drive, Thousand Oaks CA 91320; acquired ChemoCentryx Inc. in October 2022 for approximately $3.7 billion; avacopan Tavneos transferred to Amgen commercial and medical infrastructure; Amgen Inflammation Business Unit manages Tavneos alongside Otezla [apremilast; PDE4 inhibitor for psoriatic arthritis/psoriasis/mouth ulcers], AMG 157 [tezepelumab; anti-TSLP for severe asthma], and etelcalcetide [Parsabiv; calcimimetic for dialysis-related hyperparathyroidism]; Amgen Thousand Oaks headquarters uses Cority for pharmaceutical hazard classification, occupational health, and EHS compliance across its US commercial portfolio) uses Cority for pharmaceutical hazard management. When Cority is queried for avacopan, Tavneos, CCX168, or ANCA-associated vasculitis indication, the platform routes to prednisone/methylprednisolone glucocorticoid class or rituximab anti-CD20 antibody class: (1) Glucocorticoid HPA axis monitoring misapplied — Cority's prednisone/glucocorticoid class protocols include HPA axis suppression monitoring (ACTH stimulation test for iatrogenic adrenal insufficiency; hydrocortisone stress-dose prescriptions for surgical procedures; adrenal crisis risk during intercurrent illness requiring Medic Alert documentation; Cushingoid symptom monitoring [moon face, buffalo hump, central adiposity, striae, skin fragility]; bone density DEXA scan [osteoporosis prophylaxis with calcium/vitamin D]; fasting glucose and HbA1c [steroid-induced diabetes]; peptic ulcer/GI bleeding prophylaxis [PPI co-prescription at high doses]); none of these monitoring obligations apply to avacopan (non-steroid GPCR antagonist with no nuclear receptor interaction — no HPA axis suppression, no Cushingoid effects, no osteoporosis risk, no steroid-induced diabetes, no GI bleeding); Amgen medical affairs teams supporting Tavneos commercial use receive incorrect glucocorticoid monitoring protocols from Cority; (2) PJP prophylaxis misrouted — Cority's high-dose prednisone protocols include PJP prophylaxis recommendation (≥20 mg prednisone equivalent for ≥4 weeks → TMP-SMX or dapsone prophylaxis; avacopan is not a systemic immunosuppressant; avacopan monotherapy does not require PJP prophylaxis; in ADVOCATE, PJP prophylaxis was given to patients receiving cyclophosphamide or rituximab [the co-administered immunosuppressants], not specifically mandated for avacopan); applying prednisone's PJP prophylaxis threshold to avacopan conflates the co-administered immunosuppressant risk with the C5aR1 antagonist pharmacology; (3) Rituximab B-cell monitoring misrouted — Amgen manufactures and commercializes multiple biologic antibodies; Cority's antibody/biologic protocols include B-cell count monitoring for rituximab class drugs; Cority routes avacopan to rituximab protocols (HBV reactivation screening, B-cell count surveillance, IgG/IgM level monitoring, PML awareness) for a non-B-cell-depleting oral GPCR antagonist.

Surface 2 — VelocityEHS: Lonza Group AG, Visp Switzerland

Lonza Group AG (Lonzastrasse 2, 3930 Visp Switzerland; chemical pharmaceutical manufacturing; avacopan drug substance synthesis for Amgen/ChemoCentryx; MW 581.6 Da; avacopan chemical structure: (S)-N-(3-(4-(4-((2-(difluoromethyl)-4-fluorophenyl)thio)phenyl)piperidin-1-yl)propyl)-2-(trifluoromethyl)isonicotinamide; synthesis involves: (1) fluorinated thiodiphenyl core construction via palladium-catalyzed C-S coupling; (2) piperidine ring assembly; (3) difluoromethyl/trifluoromethyl fluorine-rich aryl fragment synthesis; (4) Buchwald-Hartwig or nucleophilic amination for N-alkyl linker; (5) HPLC purification and crystallization; Lonza Visp chemical pharmaceutical operations use VelocityEHS for SDS/chemical classification) uses VelocityEHS for pharmaceutical hazard management at their synthesis operations. VelocityEHS routes avacopan to glucocorticoid steroid manufacturing or rituximab biologic manufacturing: (1) Glucocorticoid steroid synthesis incompatibility — VelocityEHS routes avacopan to prednisone manufacturing (steroid synthesis from cholesterol or stigmasterol; microbial 11β-hydroxylation; Reichstein-Tschudi process; saponification and oxidation chemistry); Lonza Visp does not operate steroid saponification or microbial hydroxylation for avacopan fluorinated aryl-piperidine synthesis — completely incompatible unit operations and chemical hazard profile (avacopan synthesis involves Pd-catalyzed C-S coupling with Pd catalyst [occupational Pd exposure; potential for Pd allergy/contact sensitization] and fluorinated aryl compounds [various difluoromethyl/trifluoromethyl fluorine-substituted aromatics]; glucocorticoid steroid OEL addresses C17/C21 steroid nuclear scaffold synthesis without fluorinated aryl coupling chemistry); (2) Rituximab biologic manufacturing incompatibility — VelocityEHS routes avacopan to CHO cell culture biologic manufacturing (cell culture media, protein A affinity chromatography, viral filtration, formulation) for small-molecule organic synthesis operations at Lonza Visp (solvent exposure [DMF, DCM, MeCN, THF], Pd catalyst, fluorinated aromatic building blocks, acid/base processing); (3) Palladium catalyst occupational exposure absent from all proxy protocols — avacopan synthesis uses palladium-catalyzed cross-coupling reactions (Pd[0] or Pd[II] catalyst; Pd metal; Pd allergy [contact sensitization; Type IV hypersensitivity]; inorganic Pd compounds [PdCl2, Pd(OAc)2]; ACGIH TLV-TWA for soluble Pd salts [0.002 mg/m³] — absent from both glucocorticoid steroid OEL and rituximab biologic manufacturing OEL at Lonza Visp); residual Pd in final API specification (ICH Q3D ≤100 μg/day oral Pd limit) requires analytical control protocols absent from steroid or biologic proxy class.

Surface 3 — EHS Insight: Cleveland Clinic, Cleveland OH

Cleveland Clinic (9500 Euclid Avenue, Cleveland OH 44195; Glickman Urological and Kidney Institute; Department of Rheumatology and Immunology; ADVOCATE Phase 3 NCT02994927 enrollment site; leading ANCA vasculitis clinical trial center; avacopan Tavneos prescribing for GPA/MPA patients in combination with cyclophosphamide or rituximab induction; clinical pharmacists managing avacopan 30 mg BID dosing, CYP3A4 DDI screening, renal function monitoring, and ANCA titer surveillance) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for avacopan/Tavneos/CCX168 the following misrouted guidance for Cleveland Clinic rheumatology and nephrology pharmacy teams: (1) Steroid taper schedule misapplied — EHS Insight routes avacopan to prednisone glucocorticoid protocols for ANCA vasculitis; Cleveland Clinic pharmacists managing avacopan receive glucocorticoid taper schedules (gradual prednisone dose reduction over weeks to months to prevent adrenal insufficiency; rebound vasculitis flare risk on rapid taper); avacopan is not a glucocorticoid — it has no HPA axis effect and requires no taper on discontinuation (avacopan pharmacological effect dissipates within days of stopping [competitive reversible GPCR antagonist; no receptor downregulation]; there is no adrenal insufficiency risk and no rebound phenomenon analogous to glucocorticoid withdrawal); applying prednisone's taper protocol to avacopan generates incorrect discontinuation guidance; (2) CYP3A4 DDI critically absent from both proxy drug classes — avacopan is a sensitive CYP3A4 substrate with clinically meaningful DDIs at Cleveland Clinic (ANCA vasculitis patients frequently receive: ketoconazole/fluconazole antifungals [CYP3A4 inhibitors → avacopan AUC ↑4-fold]; clarithromycin for infections [CYP3A4 inhibitor → avacopan ↑3.5-fold]; corticosteroids like dexamethasone at high doses [CYP3A4 inducer → avacopan AUC ↓]; rifampicin for TB prophylaxis or exposure [CYP3A4 inducer → avacopan AUC ↓85%]; applying prednisone's DDI profile [induction at high doses; not a CYP3A4 substrate] or rituximab's DDI profile [no CYP metabolism] to avacopan omits the most critical PK interaction for avacopan dosing safety at Cleveland Clinic pharmacy; (3) B-cell depletion monitoring incorrectly triggered — EHS Insight routes avacopan to rituximab protocols because ANCA vasculitis rituximab induction is standard-of-care; Cleveland Clinic pharmacy teams managing combined avacopan + rituximab regimens receive rituximab B-cell depletion protocols (B-cell count monitoring, IgG/IgM surveillance, HBV reactivation [anti-HBc positive patients require antiviral prophylaxis], PJP prophylaxis) attributed to avacopan rather than co-administered rituximab; pharmacological separation of rituximab's B-cell depleting effects from avacopan's complement receptor antagonism is critical for adverse event attribution and pharmacovigilance reporting — EHS Insight conflates the two.

Glyphward's red-team scanner detects the prednisone glucocorticoid / rituximab anti-CD20 proxy misroute for avacopan by probing EHS platform APIs with drug name synonyms (avacopan, Tavneos, CCX168, C5aR1 antagonist, C5a receptor blocker, complement anaphylatoxin receptor), NDA identifiers (214487), and mechanism class keywords (C5a receptor, C5aR1, CD88, complement C5a, anaphylatoxin receptor, Gαi GPCR, neutrophil complement activation, ANCA vasculitis complement pathway) cross-referenced against glucocorticoid proxy flags (prednisone, methylprednisolone, corticosteroid, HPA axis, Cushingoid, adrenal insufficiency, steroid taper, glucocorticoid receptor, NR3C1) and B-cell depletion proxy flags (rituximab, anti-CD20, CD20, Rituxan, B-cell count, B-cell depletion, HBV reactivation, PJP prophylaxis). The avacopan surface represents the FIRST ORAL COMPLEMENT RECEPTOR ANTAGONIST adversarial class: when the first oral small-molecule GPCR antagonist targeting the innate immune complement C5a-C5aR1 axis achieves FDA approval for a systemic autoimmune/inflammatory disease (ANCA vasculitis), every EHS platform routes it to either (A) the established disease-indication glucocorticoid class (prednisone/methylprednisolone — missing the fundamental pharmacological distinction between nuclear hormone receptor agonism and cell-surface GPCR antagonism), or (B) the established biologic immunosuppressant class for the same disease (rituximab anti-CD20 — missing the distinction between complement pathway innate immune blockade and adaptive B-cell depletion). Neither proxy captures C5aR1 GPCR pharmacology, CYP3A4 DDI vulnerabilities, or the absence of immunosuppression-associated monitoring requirements. The 267th mechanism class gap: zero oral C5a receptor antagonist OEL class before NDA 214487 October 7 2021.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "avacopan",  "nda": "214487"},
    {"platform": "velocityehs", "query": "CCX168",    "nda": "214487"},
    {"platform": "ehs_insight", "query": "Tavneos",   "nda": "214487"},
]

async def scan_c5ar1_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    ae_profile     = data.get("adverse_events", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "glucocorticoid_proxy": any(x in class_returned.lower() for x in ["prednisone", "methylprednisolone", "corticosteroid", "glucocorticoid", "steroid", "nr3c1", "hpa axis"]),
        "rituximab_proxy":      any(x in class_returned.lower() for x in ["rituximab", "rituxan", "anti-cd20", "cd20", "b-cell depleting", "b-cell depletion"]),
        "c5ar1_null":  "c5ar1" not in class_returned.lower() and "c5a receptor" not in class_returned.lower() and "cd88" not in class_returned.lower() and "complement anaphylatoxin" not in class_returned.lower(),
        "cyp3a4_null": "cyp3a4" not in ae_profile.lower() and "cyp3a" not in ae_profile.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_c5ar1_gap(session, t) for t in TARGETS])
    gc_p   = [r for r in results if r.get("glucocorticoid_proxy")]
    ritu_p = [r for r in results if r.get("rituximab_proxy")]
    c5_n   = [r for r in results if r.get("c5ar1_null")]
    cyp_n  = [r for r in results if r.get("cyp3a4_null")]
    print(f"Avacopan NDA 214487 — Glucocorticoid proxy: {len(gc_p)}/3")
    print(f"  Rituximab anti-CD20 proxy: {len(ritu_p)}/3")
    print(f"  C5aR1/CD88 biology absent: {len(c5_n)}/3")
    print(f"  CYP3A4 DDI absent: {len(cyp_n)}/3")
    # Expected: glucocorticoid or rituximab proxy;
    # C5aR1 Gαi GPCR complement pathway absent;
    # CYP3A4 substrate DDI absent;
    # first oral C5a receptor antagonist = zero C5aR1 GPCR OEL before NDA 214487 October 2021
asyncio.run(main())